No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker GSK said on Thursday that Japan's Ministry of Health, Labour and Welfare has approved a prefilled syringe version of its shingles vaccine Shingrix, offering a simpler, readytouse presentation for healthcare professionals.
GSK said the vaccine was previously supplied in two separate vials that required manual mixing before administration, with the new format removing that step, streamlining use in clinical settings.
Shingrix, a nonlive recombinant subunit vaccine, has been approved in Japan for adults aged 50 and over since 2018, and for adults 18 and over at increased risk of herpes zoster since 2023.
Around 1.1m people in Japan develop shingles each year, with risk rising with age and among those with weakened immune systems.
GSK's head of vaccines and infectious diseases R&D, Sanjay Gurunathan, said: "Shingles is a disease that 1 in 3 adults globally will develop in their lifetime. It can have serious and long-lasting complications. GSK is pleased to support the healthcare community in Japan by making administration of our shingles vaccine easier.
"GSK's prefilled syringe launched in the US in February 2026 and is launching in Europe throughout this year. Approvals are based on data confirming technical comparability between the prefilled syringe and the existing vaccine presentation. The new presentation does not involve a change in indication or dosing."
As of 0850 BST, GSK shares were 0.42% softer at 1,796p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS on Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.